Next Article in Journal
Interactions of a Dopamine D1 Receptor Agonist with Glutamate NMDA Receptor Antagonists on the Volitional Consumption of Ethanol by the mHEP Rat
Next Article in Special Issue
Delivery of RNAi-Based Oligonucleotides by Electropermeabilization
Previous Article in Journal
Protein Kinase C Inhibitors as Modulators of Vascular Function and Their Application in Vascular Disease
Previous Article in Special Issue
Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2013, 6(4), 440-468;

Design of siRNA Therapeutics from the Molecular Scale

Department of Chemical Engineering and Materials Science, Michigan State University, 428 S. Shaw Lane, Room 2527, East Lansing, MI 48824, USA
Author to whom correspondence should be addressed.
Received: 24 January 2013 / Revised: 27 February 2013 / Accepted: 13 March 2013 / Published: 25 March 2013
(This article belongs to the Special Issue RNAi-Based Therapeutics)
Full-Text   |   PDF [679 KB, uploaded 25 March 2013]   |  


While protein-based therapeutics is well-established in the market, development of nucleic acid therapeutics has lagged. Short interfering RNAs (siRNAs) represent an exciting new direction for the pharmaceutical industry. These small, chemically synthesized RNAs can knock down the expression of target genes through the use of a native eukaryotic pathway called RNA interference (RNAi). Though siRNAs are routinely used in research studies of eukaryotic biological processes, transitioning the technology to the clinic has proven challenging. Early efforts to design an siRNA therapeutic have demonstrated the difficulties in generating a highly-active siRNA with good specificity and a delivery vehicle that can protect the siRNA as it is transported to a specific tissue. In this review article, we discuss design considerations for siRNA therapeutics, identifying criteria for choosing therapeutic targets, producing highly-active siRNA sequences, and designing an optimized delivery vehicle. Taken together, these design considerations provide logical guidelines for generating novel siRNA therapeutics. View Full-Text
Keywords: siRNA therapeutic; RNAi; liver cancer; siRNA design; delivery vehicle design siRNA therapeutic; RNAi; liver cancer; siRNA design; delivery vehicle design

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Angart, P.; Vocelle, D.; Chan, C.; Walton, S.P. Design of siRNA Therapeutics from the Molecular Scale. Pharmaceuticals 2013, 6, 440-468.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top